News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Pyxis Oncology Receives FDA Fast Track Designation for PYX-201 in Head and Neck Cancer Treatment
Thursday, February 27, 2025Pyxis Oncology Inca clinicalstage company developing advanced cancer therapies has been granted Fast Track Designation by the US Food and Drug Administration FDA for PYX This designation applies to the treatment of adults with recurrent
IPA and RIBOPRO Collaborate to Advance mRNA-Driven Antibody Discovery in Immunotherapy
Thursday, February 27, 2025ImmunoPrecise Antibodies Ltd a global company specialising in AIpowered antibody discovery and development has formed a strategic collaboration with RIBOPRO a technology provider focused on mRNA and lipid nanoparticle LNP technologies
Allogene Therapeutics Strengthens Partnership with Foresight Diagnostics to Support Development Efforts Beyond the US in Europe, the UK, Canada, and Australia
Wednesday, February 26, 2025Allogene Therapeutics Inc a clinicalstage biotechnology company focused on developing allogeneic CAR T AlloCAR T therapies for cancer and autoimmune diseases has broadened its partnership with Foresight Diagnostics Inc
Bavarian Nordic Collaborates with Biological E Limited to Improve Global Availability of Chikungunya Vaccine
Wednesday, February 26, 2025Bavarian Nordic AS has partnered with Biological E Limited BE to improve access to its chikungunya vaccine in low and middleincome countries The agreement initially focuses on contract manufacturing allowing for an increase in production capacity to...
LTZ Therapeutics Receives FDA Approval for IND Application to Begin Trial of Novel Myeloid Engager Immunotherapy LTZ-301
Tuesday, February 25, 2025LTZ Therapeutics a biotechnology company focused on immunotherapy has received approval from the US Food and Drug Administration FDA for its Investigational New Drug IND application for LTZ This firstinclass myeloid engager immunotherapy is designed...
FDA Approves Mirum’s CTEXLI™ (Chenodiol) Tablets for Treating Cerebrotendinous Xanthomatosis (CTX)
Tuesday, February 25, 2025Mirum Pharmaceuticals Inc has received approval from the US Food and Drug Administration FDA for CTEXLI chenodiol tablets a bile acid treatment for adults with cerebrotendinous xanthomatosis CTX CTEXLI is the first and only approved treatment for thi...
Summit Therapeutics and Pfizer Collaborate on Clinical Trial for Ivonescimab and Antibody Drug Conjugates
Tuesday, February 25, 2025Summit Therapeutics has announced a collaboration with Pfizer to conduct clinical trials evaluating ivonescimab an investigational PDVEGF bispecific antibody in combination with Pfizers antibody drug conjugates ADCs for the treatment of various solid...
Summit Therapeutics to Work with Pfizer on Clinical Trial Assessing Ivonescimab with Antibody Drug Conjugates
Monday, February 24, 2025Summit Therapeutics Inchas announced a clinical trial collaboration with Pfizer Incto assess ivonescimab an investigational PD VEGF bispecific antibody in combination with several of Pfizers antibodydrug conjugates ADCs across multiple solid tumour...
PolarityBio Gains U.S. FDA Breakthrough Therapy Status for Wagner Grade I Diabetic Foot Ulcer Treatment
Friday, February 21, 2025PolarityBio a biotechnology company focused on regenerative tissue products has announced that its SkinTE treatment has received Breakthrough Therapy Status from the US Food and Drug Administration FDA for Wagner Grade Diabetic Foot Ulcers DFU This...
Elixirgen Therapeutics Gains FDA Orphan Drug Status for EXG-34217 to Treat Telomere Biology Disorders
Friday, February 21, 2025Elixirgen Therapeutics a biotechnology company focused on rare diseases has received Orphan Drug Status from the US Food and Drug Administration FDA for EXG a gene therapy for Telomere Biology Disorders TBDs
